Core Viewpoint - The article emphasizes the investment potential in the domestic high-value medical consumables and innovative pharmaceuticals sectors, highlighting significant growth opportunities and market undervaluation in these areas [1][6][34]. Group 1: Investment Logic of Core Assets - The primary investment direction for the fund is domestic high-value medical consumables, which have substantial growth potential and are currently undervalued in the market. The market capitalization disparity between domestic and international players is significant, with domestic high-value consumables having a maximum market cap of over 30 billion RMB compared to nearly 1 trillion RMB for their international counterparts [1][3]. - The penetration rate of high-value consumables in China is still low, indicating a potential for significant growth as domestic adoption increases and international markets are explored [3]. - The "innovation + internationalization" logic driving the revaluation of innovative drugs also applies to domestic high-value consumables, with rapid growth in overseas revenues for listed cardiovascular high-value consumables companies, indicating increasing international recognition [4]. Group 2: Domestic Innovative Pharmaceuticals - Domestic innovative pharmaceuticals represent the second major investment direction, driven by strong market momentum. The revenue for Hong Kong-listed innovative drugs is expected to grow from less than 10 billion RMB in 2020 to nearly 100 billion RMB by 2026 [6]. - The deep medical reform initiated in China since 2015 is expected to create a long-term growth cycle for innovative pharmaceuticals, similar to the one experienced in the U.S. after its reforms in the 1980s [6][8]. - The transition from the first half of the cycle (2015-2025) to the second half (2025-2035) will require identifying underpriced potential blockbuster products to sustain excess returns in innovative drug investments [7][8]. Group 3: U.S. Biotechnology - The third major investment direction is U.S. biotechnology, where many early-stage biotech companies have not yet been fully valued despite their significant growth potential. The focus is particularly on intracellular therapies, which have seen dramatic price fluctuations [10][11]. - The fund prioritizes liver-targeted siRNA and gene editing technologies, with the former showing clearer commercialization prospects and rapid valuation recovery [11]. Group 4: Undervalued/Barrier Assets - The fourth major investment direction is undervalued barrier assets, which are currently less popular compared to innovative pharmaceuticals. These assets are expected to experience a trend of recovery in the next three years, making them attractive for investment [13][14]. - The fund has adjusted its structure to focus on undervalued assets in the pharmaceutical distribution sector, which are expected to have clear value propositions due to anticipated performance acceleration [14]. Group 5: Investment Review and Reflection - In 2025, the fund underestimated the revenue growth pressures on non-innovative pharmaceutical assets and the scale of innovative drug licensing deals [16]. - The fund's performance was impacted by lower-than-expected revenue growth in domestic high-value consumables, highlighting the need for better research efficiency and timely coverage of promising stocks [20][21]. Group 6: Industry Trends and Outlook - The pharmaceutical industry's profitability is expected to restart rapid growth, with current market valuations not reflecting this potential, indicating possible investment opportunities [34]. - The overall pharmaceutical sector may shift from being dominated by innovative drugs to a more balanced growth model that includes a wider range of pharmaceutical assets [34][31].

Core Viewpoint - The article emphasizes the importance of establishing a stable and self-consistent valuation system for guiding investment decisions, despite the inherent subjectivity and variability in company valuations [1][2]. Group 1: Valuation Channel - In a relatively stable market, companies' valuations fluctuate within a defined "valuation channel," which varies by company quality [3][6]. - The theory suggests that buying excellent companies at a premium can yield higher returns over time compared to buying mediocre companies at a discount [3][7]. - The concept of valuation channels serves as a useful metric for assessing market sentiment and identifying discrepancies in expected valuations [8]. Group 2: Valuation Leap Triggered by Business Dynamics - Valuation channels are maintained under stable market expectations, but significant changes in business growth expectations can disrupt these channels, leading to valuation leaps [9][10]. - Valuation leaps can occur rapidly, often within months, due to substantial adjustments in market expectations rather than actual performance changes [10][12]. - Historical examples illustrate that companies previously undervalued can experience upward valuation leaps when market sentiment shifts positively [11][12]. Group 3: External Market Influences - Many valuation leaps are driven by macroeconomic factors rather than fundamental business changes, leading to significant price fluctuations in stocks [14][15]. - The article notes that during market downturns, companies with stable fundamentals can still experience drastic valuation declines due to negative market sentiment [15][17]. - The current market environment has created opportunities for identifying undervalued companies with strong growth potential amidst external pressures [18]. Group 4: Case Studies and Future Outlook - The article discusses specific case studies in the Hong Kong and U.S. biotech sectors, highlighting the potential for significant valuation recovery in undervalued companies [19][20]. - It emphasizes the importance of understanding the underlying business dynamics and market narratives that influence valuation trends [36][39]. - The article concludes that while the market may currently undervalue certain biotech companies, their long-term growth potential remains strong, suggesting future investment opportunities [42][43].